Form 4 for MBRX Moleculin Biotech, Inc.
Accepted 2025-06-23 00:00:00 ET · period of report 2025-06-20 · accession 0001437749-25-021051 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-06-23 | 2025-06-20+ | MBRX | Foster Jonathan P. | CFO | M - OptEx | — | +7,039 | 18.4K | +62% | — |
| DM | 2025-06-23 | 2025-06-20+ | MBRX | Foster Jonathan P. | CFO | F - Tax | $0.27 | -1,715 | 14.0K | -11% | -$463.05 |
| D | 2025-06-23 | 2025-06-23 | MBRX | Foster Jonathan P. | CFO | P - Purchase | $0.37 | +270.3K | 287.6K | +1,561% | +$100.0K |
| DM | 2025-06-23 | 2025-06-20+ | MBRX | Foster Jonathan P. | CFO | M - OptEx | $0.00 | -7,039 | 231.8K | -3% | $0 |
| D | 2025-06-23 | 2025-06-23 | MBRX | Foster Jonathan P. | CFO | P - Purchase | — | -810.8K | 1.04M | -44% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-20 | M | A | 2,711 | — | 14,704 | D | — | — | (F1) Restricted stock units convert into common stock on a one-for-one basis. |
| 2 | Common | Common Stock | 2025-06-22 | F | D | 1,054 | $0.27 | 17,317 | D | — | — | (F2) Shares withheld for payment of taxes upon vesting of restricted stock unit awards. |
| 3 | Common | Common Stock | 2025-06-22 | M | A | 4,328 | — | 18,371 | D | — | — | (F1) Restricted stock units convert into common stock on a one-for-one basis. |
| 4 | Common | Common Stock | 2025-06-20 | F | D | 661 | $0.27 | 14,043 | D | — | — | (F2) Shares withheld for payment of taxes upon vesting of restricted stock unit awards. |
| 5 | Common | Common Stock | 2025-06-23 | P | A | 270,270 | $0.37 | 287,587 | D | — | — | (F5) On June 23, 2025, the reporting person acquired 270,270 shares of common stock and Series E warrants to purchase 810,810 shares of common stock at a purchase price of $0.37 per share and accompanying warrants in a public offering. The Series E warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series E warrants and will expire five years from the date of such approval. |
| 6 | Derivative | Restricted Stock Units | 2025-06-22 | M | D | 4,328 | $0.00 | 227,510 | D | — · — to — | 4,328 Common Stock | (F1) Restricted stock units convert into common stock on a one-for-one basis. (F4) On June 22, 2023, the reporting person was granted 17,313 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. |
| 7 | Derivative | Restricted Stock Units | 2025-06-20 | M | D | 2,711 | $0.00 | 231,838 | D | — · — to — | 2,711 Common Stock | (F1) Restricted stock units convert into common stock on a one-for-one basis. (F3) On June 20, 2022, the reporting person was granted 10,846 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. |
| 8 | Derivative | Series E Warrants | 2025-06-23 | P | D | 810,810 | — | 1,038,320 | D | $0.37 · — to — | 810,810 Common Stock | (F5) On June 23, 2025, the reporting person acquired 270,270 shares of common stock and Series E warrants to purchase 810,810 shares of common stock at a purchase price of $0.37 per share and accompanying warrants in a public offering. The Series E warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series E warrants and will expire five years from the date of such approval. |